ChloroquineV1, Main, Exploration, bibRecord, 001C62

Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease

Identifieur interne : 001C62 ( Main/Exploration ); précédent : 001C61; suivant : 001C63

Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease

Auteurs : A. Holvast [Pays-Bas] ; A. Huckriede [Pays-Bas] ; J. Wilschut [Pays-Bas] ; G. Horst [Pays-Bas] ; J J C. De Vries [Pays-Bas] ; C A Benne [Pays-Bas] ; C G M. Kallenberg [Pays-Bas] ; M. Bijl [Pays-Bas]

Source :

Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2006-07.

RBID : ISTEX:3E5E528679D6A4F1B868379119089A10DF335CF5

English descriptors

Abstract

Objective: to assess the safety and efficacy of influenza vaccination in patients with systemic lupus erythematosus (SLE), and to evaluate the influence of immunosuppressive drugs on the immune response. Methods: SLE patients (n = 56) and healthy controls (n = 18) were studied. All patients had quiescent disease (SLE disease activity index ⩽5). Four patient groups were defined on the basis of their drug use: (1) no drug treatment; (2) hydroxychloroquine treatment; (3) azathioprine treatment; (4) prednisone treatment. Participants received trivalent influenza subunit vaccine during October/November 2003. Disease activity scores and side effects were recorded. Antibody titres against influenza virus were measured before and 30 days after vaccination using the haemagglutination inhibition assay. Results: Influenza vaccination did not result in changes in disease activity and was well tolerated. SLE patients had fewer seroconversions or fourfold titre rises for A/H1N1 (p<0.001) and A/H3N2 (p<0.001) than healthy controls, while for B/Hong Kong the difference was of borderline significance (p = 0.051). With regard to immunosuppressive treatment, fewer SLE patients using azathioprine developed fourfold titre rises against A/H3N2 (p = 0.041), and fewer achieved titres of ⩾40 against A/H3N2 (p = 0.030) compared with the other patient groups. Conclusions: Influenza vaccination in SLE patients with quiescent disease is safe but is less effective than in controls. Use of azathioprine was associated with a trend to decreased vaccination efficacy.

Url:

https://api.istex.fr/ark:/67375/NVC-0J80TCVB-9/fulltext.pdf

DOI: 10.1136/ard.2005.043943

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001010
to stream Istex, to step Curation: 001010
to stream Istex, to step Checkpoint: 000B30
to stream Main, to step Merge: 001C74
to stream Main, to step Curation: 001C62

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease</title>
<author><name sortKey="Holvast, A" sort="Holvast, A" uniqKey="Holvast A" first="A" last="Holvast">A. Holvast</name>
</author>
<author><name sortKey="Huckriede, A" sort="Huckriede, A" uniqKey="Huckriede A" first="A" last="Huckriede">A. Huckriede</name>
</author>
<author><name sortKey="Wilschut, J" sort="Wilschut, J" uniqKey="Wilschut J" first="J" last="Wilschut">J. Wilschut</name>
</author>
<author><name sortKey="Horst, G" sort="Horst, G" uniqKey="Horst G" first="G" last="Horst">G. Horst</name>
</author>
<author><name sortKey="De Vries, J J C" sort="De Vries, J J C" uniqKey="De Vries J" first="J J C" last="De Vries">J J C. De Vries</name>
</author>
<author><name sortKey="Benne, C A" sort="Benne, C A" uniqKey="Benne C" first="C A" last="Benne">C A Benne</name>
</author>
<author><name sortKey="Kallenberg, C G M" sort="Kallenberg, C G M" uniqKey="Kallenberg C" first="C G M" last="Kallenberg">C G M. Kallenberg</name>
</author>
<author><name sortKey="Bijl, M" sort="Bijl, M" uniqKey="Bijl M" first="M" last="Bijl">M. Bijl</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3E5E528679D6A4F1B868379119089A10DF335CF5</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1136/ard.2005.043943</idno>
<idno type="url">https://api.istex.fr/ark:/67375/NVC-0J80TCVB-9/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001010</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001010</idno>
<idno type="wicri:Area/Istex/Curation">001010</idno>
<idno type="wicri:Area/Istex/Checkpoint">000B30</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B30</idno>
<idno type="wicri:doubleKey">0003-4967:2006:Holvast A:safety:and:efficacy</idno>
<idno type="wicri:Area/Main/Merge">001C74</idno>
<idno type="wicri:Area/Main/Curation">001C62</idno>
<idno type="wicri:Area/Main/Exploration">001C62</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease</title>
<author><name sortKey="Holvast, A" sort="Holvast, A" uniqKey="Holvast A" first="A" last="Holvast">A. Holvast</name>
<affiliation wicri:level="4"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Immunology, University Medical Center Groningen, University of Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue (ville)</settlement>
<region>Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
</author>
<author><name sortKey="Huckriede, A" sort="Huckriede, A" uniqKey="Huckriede A" first="A" last="Huckriede">A. Huckriede</name>
<affiliation wicri:level="3"><country>Pays-Bas</country>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<wicri:orgArea>Department of Medical Microbiology, Molecular Virology Section</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Wilschut, J" sort="Wilschut, J" uniqKey="Wilschut J" first="J" last="Wilschut">J. Wilschut</name>
<affiliation wicri:level="3"><country>Pays-Bas</country>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<wicri:orgArea>Department of Medical Microbiology, Molecular Virology Section</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Horst, G" sort="Horst, G" uniqKey="Horst G" first="G" last="Horst">G. Horst</name>
<affiliation wicri:level="4"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Immunology, University Medical Center Groningen, University of Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue (ville)</settlement>
<region>Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
</author>
<author><name sortKey="De Vries, J J C" sort="De Vries, J J C" uniqKey="De Vries J" first="J J C" last="De Vries">J J C. De Vries</name>
<affiliation wicri:level="3"><country>Pays-Bas</country>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<wicri:orgArea>Laboratory for Infectious Diseases</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Benne, C A" sort="Benne, C A" uniqKey="Benne C" first="C A" last="Benne">C A Benne</name>
<affiliation wicri:level="3"><country>Pays-Bas</country>
<placeName><settlement type="city">Groningue</settlement>
<region nuts="2" type="province">Groningue (province)</region>
</placeName>
<wicri:orgArea>Laboratory for Infectious Diseases</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Kallenberg, C G M" sort="Kallenberg, C G M" uniqKey="Kallenberg C" first="C G M" last="Kallenberg">C G M. Kallenberg</name>
<affiliation wicri:level="4"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Immunology, University Medical Center Groningen, University of Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue (ville)</settlement>
<region>Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
</author>
<author><name sortKey="Bijl, M" sort="Bijl, M" uniqKey="Bijl M" first="M" last="Bijl">M. Bijl</name>
<affiliation wicri:level="4"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical Immunology, University Medical Center Groningen, University of Groningen</wicri:regionArea>
<placeName><settlement type="city">Groningue (ville)</settlement>
<region>Groningue (province)</region>
</placeName>
<orgName type="university">Université de Groningue</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of the Rheumatic Diseases</title>
<title level="j" type="abbrev">Ann Rheum Dis</title>
<idno type="ISSN">0003-4967</idno>
<idno type="eISSN">1468-2060</idno>
<imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher>
<date type="published" when="2006-07">2006-07</date>
<biblScope unit="volume">65</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="913">913</biblScope>
</imprint>
<idno type="ISSN">0003-4967</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0003-4967</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>GMT, geometric mean titre</term>
<term>SLE</term>
<term>SLE, systemic lupus erythematosus</term>
<term>SLEDAI, SLE disease activity index</term>
<term>VAS, visual analogue score</term>
<term>efficacy</term>
<term>influenza vaccination</term>
<term>safety</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Antibody response</term>
<term>Azathioprine</term>
<term>Azathioprine group</term>
<term>Center groningen</term>
<term>Disease activity</term>
<term>Disease activity index</term>
<term>Drug treatment</term>
<term>Erythematosus</term>
<term>Exact test</term>
<term>Gmt</term>
<term>Groningen</term>
<term>Healthy controls</term>
<term>Huckriede</term>
<term>Humoral</term>
<term>Hydroxychloroquine</term>
<term>Immune</term>
<term>Immune response</term>
<term>Immunocompromised patients</term>
<term>Immunogenicity</term>
<term>Immunosuppressive</term>
<term>Immunosuppressive drug treatment</term>
<term>Immunosuppressive drugs</term>
<term>Influenza</term>
<term>Influenza immunization</term>
<term>Influenza vaccination</term>
<term>Influenza vaccine</term>
<term>Lower immunogenicity</term>
<term>Lupus</term>
<term>More patients</term>
<term>Other patient groups</term>
<term>Patient groups</term>
<term>Pneumococcal vaccination</term>
<term>Previous season</term>
<term>Quiescent disease</term>
<term>Seroconversions</term>
<term>Side effects</term>
<term>Significant effect</term>
<term>Sledai</term>
<term>Solvay pharmaceuticals</term>
<term>Systemic</term>
<term>Systemic lupus erythematosus</term>
<term>Titre</term>
<term>Vaccination</term>
<term>Vaccination efficacy</term>
<term>Vaccination kong</term>
<term>Vaccine</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: to assess the safety and efficacy of influenza vaccination in patients with systemic lupus erythematosus (SLE), and to evaluate the influence of immunosuppressive drugs on the immune response. Methods: SLE patients (n = 56) and healthy controls (n = 18) were studied. All patients had quiescent disease (SLE disease activity index ⩽5). Four patient groups were defined on the basis of their drug use: (1) no drug treatment; (2) hydroxychloroquine treatment; (3) azathioprine treatment; (4) prednisone treatment. Participants received trivalent influenza subunit vaccine during October/November 2003. Disease activity scores and side effects were recorded. Antibody titres against influenza virus were measured before and 30 days after vaccination using the haemagglutination inhibition assay. Results: Influenza vaccination did not result in changes in disease activity and was well tolerated. SLE patients had fewer seroconversions or fourfold titre rises for A/H1N1 (p<0.001) and A/H3N2 (p<0.001) than healthy controls, while for B/Hong Kong the difference was of borderline significance (p = 0.051). With regard to immunosuppressive treatment, fewer SLE patients using azathioprine developed fourfold titre rises against A/H3N2 (p = 0.041), and fewer achieved titres of ⩾40 against A/H3N2 (p = 0.030) compared with the other patient groups. Conclusions: Influenza vaccination in SLE patients with quiescent disease is safe but is less effective than in controls. Use of azathioprine was associated with a trend to decreased vaccination efficacy.</div>
</front>
</TEI>
<affiliations><list><country><li>Pays-Bas</li>
</country>
<region><li>Groningue (province)</li>
</region>
<settlement><li>Groningue</li>
<li>Groningue (ville)</li>
</settlement>
<orgName><li>Université de Groningue</li>
</orgName>
</list>
<tree><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Holvast, A" sort="Holvast, A" uniqKey="Holvast A" first="A" last="Holvast">A. Holvast</name>
</region>
<name sortKey="Benne, C A" sort="Benne, C A" uniqKey="Benne C" first="C A" last="Benne">C A Benne</name>
<name sortKey="Bijl, M" sort="Bijl, M" uniqKey="Bijl M" first="M" last="Bijl">M. Bijl</name>
<name sortKey="De Vries, J J C" sort="De Vries, J J C" uniqKey="De Vries J" first="J J C" last="De Vries">J J C. De Vries</name>
<name sortKey="Horst, G" sort="Horst, G" uniqKey="Horst G" first="G" last="Horst">G. Horst</name>
<name sortKey="Huckriede, A" sort="Huckriede, A" uniqKey="Huckriede A" first="A" last="Huckriede">A. Huckriede</name>
<name sortKey="Kallenberg, C G M" sort="Kallenberg, C G M" uniqKey="Kallenberg C" first="C G M" last="Kallenberg">C G M. Kallenberg</name>
<name sortKey="Wilschut, J" sort="Wilschut, J" uniqKey="Wilschut J" first="J" last="Wilschut">J. Wilschut</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C62 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C62 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:3E5E528679D6A4F1B868379119089A10DF335CF5
   |texte=   Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease

Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri